Neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) occur in the later decades of life and have no curative therapy. Therefore, future treatments for these disorders must be administered over decades, which means that safety profiles of therapeutic targets are of utmost importance. The advent of alternative therapies such as antisense oligonucleotides, gene therapy and immunotherapy, together with traditional pharmacology have made it such that almost any molecule can be targeted. More and more, the extent to which a target is druggable hinges on the safety and specificity of its targeting over time.

We recently demonstrated that TRIM28 regulates the steady state levels of the neurodegeneration-driving proteins α-Synuclein (α-Syn) and tau (Rousseaux et al., 2016). However, given the critical roles of TRIM28 in mammalian development (Cammas et al., 2000), its tractability as a therapeutic target remains questionable. For instance, complete loss of Trim28 in mice causes early embryonic lethality due to pre-implantation defects (Cammas et al., 2000), and specific deletion of this gene in the developing tissues cause a host of defects (Cheng et al., 2014; Fasching et al., 2015; Trono, 2015). Moreover, haploinsufficiency of TRIM28 is expected to have deleterious outcomes in humans (pLI = 1.00, ExAC; [Lek et al., 2016]). This may be due in part due to the multiple functions of TRIM28 within the cell including the repression of endogenous retroviral elements, maintenance of pluripotency, epigenetics and mitophagy (Barde et al., 2013; Czerwińska et al., 2017; Oleksiewicz et al., 2017; Singh et al., 2015; Wolf and Goff, 2009). Given the importance of TRIM28 for development, it remains unclear whether TRIM28 is critical for adult brain function, and whether it may safely be targeted in adulthood. Specifically, two questions remain related to the targeting of TRIM28 pharmacologically: (1) Is there a pharmacologically tractable domain in TRIM28 that could be targeted by a drug? (2) Is genetic suppression of TRIM28 in the brain and throughout the body tolerated in adulthood? To test this, we performed studies to pinpoint the mechanism by which TRIM28 regulates α-Syn and tau and generated two animal models to disrupt Trim28 in vivo, thus establishing its druggability in adulthood.

We previously found that TRIM28 regulates the post-translational stability of α-Syn and tau and that this effect is mediated by two critical cysteines in its RING domain (C65 and C68; [Rousseaux et al., 2016]). We hypothesized that TRIM28 may act as an E3 SUMO ligase (Liang et al., 2011; Neo et al., 2015; Yang et al., 2013) toward α-Syn and tau via this domain for three reasons: (1) TRIM28 interacts only weakly with α-Syn and tau (Rousseaux et al., 2016) and is therefore unlikely to act solely as a stabilizing factor via these residues; (2) TRIM28 mediates the nuclear localization of α-Syn and tau and SUMOylation is thought to play a critical role in influencing subcellular localization (Hay, 2005); and (3) Given the post-translational stabilization effect of TRIM28 on α-Syn and tau (Rousseaux et al., 2016), we surmised that SUMOylation may help prevent polyubiquitination, thus increasing their overall bioavailability. To test whether SUMOylation itself regulates the levels of α-Syn and tau, we inhibited the sole E2 SUMO ligase, UBC9, via RNAi and pharmacological inhibition (using Viomellein [Hirohama et al., 2013]). We found that both approaches were sufficient to decrease α-Syn and tau, suggesting that SUMOylation indeed regulates their steady state levels (Figure 1A). We next asked whether TRIM28 mediates the SUMOylation of α-Syn and tau. We first tested this in cells and found that knockdown of endogenous TRIM28 decreased native α-Syn and tau SUMOylation whereas ectopic overexpression of TRIM28 increased their SUMOylation (Figure 1B). Interestingly, when we mutated a catalytic RING domain of TRIM28 (C65A/C68A), we could inhibit α-Syn and tau SUMOylation (Figure 1B). This was consistent with our previous findings that mutating this residue impeded α-Syn and tau stabilization and nuclear localization (Rousseaux et al., 2016). However, mutant TRIM28 (C65A/C68A) was less stable than its wildtype form in all assays. Thus, whether these findings are due to decreased SUMOylation or to a change in TRIM28 protein stability is difficult to discern. To further test whether Trim28 regulates α-Syn and tau SUMOylation, we performed SUMOylation assays on endogenous α-Syn and tau from brain lysates (under denaturing conditions) from wild-type and Trim28^+/- mice. We found that α-Syn and tau SUMOylation were significantly reduced in Trim28 haploinsufficient mice (Figure 1C).

Figure 1 with 1 supplement see all

Download asset Open asset

TRIM28 has several important functions throughout the cell (Cheng et al., 2014; Czerwińska et al., 2017; Dalgaard et al., 2016; Fasching et al., 2015; Liang et al., 2011; Neo et al., 2015; Singh et al., 2015), and its loss of function in mice is embryonic lethal (Cammas et al., 2000). We asked whether one of its domains can be specifically targeted for future therapeutic use without disrupting the others. Given that two conserved critical cysteine residues in its RING domain (Figure 1—figure supplement 1A) regulate TRIM28 function toward α-Syn and tau, we hypothesized that mutating residues critical for its endogenous catalytic activity would be the most promising approach. We therefore generated a knockin mouse carrying mutations in its RING domain (Figure 1—figure supplement 1B). We found that mutating these residues, despite decreasing α-Syn and tau levels significantly, caused a dramatic destabilization of TRIM28 protein (Figure 1—figure supplement 1C–D). Moreover, homozygosity for the these E3 mutant allele caused embryonic lethality, a feature consistent with the effects of a null allele. Thus, mutating the RING domain of TRIM28 decreases α-Syn and tau levels, but does so by disrupting its structure and stability (Figure 1—figure supplement 1D).

Since TRIM28 has critical roles in development, we next asked whether we could bypass these defects by knocking down Trim28 in the postnatal mouse brain (Figure 2—figure supplement 1A). We used an AAV carrying both an shRNA targeting Trim28 and a YFP reporter. We found that the virus was widely expressed throughout the brain (Kim et al., 2013) and that mice receiving an shRNA against Trim28 had a 75% depletion of Trim28 in their brain (Figure 2—figure supplement 1B). Importantly, these mice developed normally until at least 10 weeks of age. We evaluated cortical and hippocampal thickness and astrocytosis in these mice and did not note any significant defects (Figure 2—figure supplement 1C).

Given that synucleinopathies and tauopathies most often occur in the later decades of life, therapeutics should therefore accurately mimic this late-stage disruption. To test whether late stage inhibition of Trim28 is therapeutically tractable, we generated Trim28 adult knockout mice. This was done by crossing a whole body, tamoxifen-inducible Cre (UBC-CreER^T2, [Ruzankina et al., 2007]) with mice carrying a floxed Trim28 allele (Cammas et al., 2000). We waited until the animals were 8–12 weeks old before starting a 4 week tamoxifen regimen to ablate Trim28 (Figure 2A). To our surprise, we found that adult depletion did not result in early lethality nor overt phenotypes. Instead, adult knockout mice lived for the duration of the study (over 40 weeks post-tamoxifen injection, Figure 2B). We tested whether Trim28 is effectively ablated in these mice and found that Trim28 levels were reduced by over 75% in each tissue tested (both at the RNA and protein level; Figure 2C,D and Figure 2—figure supplement 2A–C). Importantly, α-Syn and tau levels were also decreased in multiple brain regions, corroborating our previous findings using germline haploinsufficient mice (Rousseaux et al., 2016).

Figure 2 with 2 supplements see all

Download asset Open asset

An important aspect of measurable safety margins in the depletion of a gene is its impact on neuronal function. To assess whether loss of Trim28 in adult mice impacts brain structure and function, we performed a battery of behavioral and histological tests. We found that Trim28 adult knockout mice behaved similarly to their control littermate counterparts in every test assayed. Specifically, no defects were observed in motor behavior, anxiety, perseverative movements and memory (Figure 3A–H). Consistent with this, we could not discern any gross histological defects nor signs of inflammation (as measured by GFAP immunoreactivity) in the brain (Figure 4A–C). We further tested Trim28 levels via immunostaining and found that, while Trim28 was highly expressed in the brain (confirming our western and qPCR results), it was depleted in the adult knockout (Figure 4—figure supplement 1A). A previous study highlighted several gene expression changes in mice lacking Trim28 in forebrain excitatory neurons starting from postnatal day 14 (Jakobsson et al., 2008). We tested the expression of these genes in the hippocampus using qPCR and found that, while the directionality of changes was consistent with the previous study, there was a broad dampening of this effect in the adult knockout mice (Figure 4—figure supplement 1B). This may be due to the later stage depletion of Trim28 or the incomplete deletion of Trim28 (there is 15–20% remaining in most adult knockouts) and may account for the slight behavioral abnormalities observed in the reported juvenile forebrain-specific Trim28 knockouts (Jakobsson et al., 2008) versus the whole-body adult Trim28 knockouts.

Figure 3

Download asset Open asset

Figure 4 with 3 supplements see all

Download asset Open asset

Given that the adult knockout affects the whole body, we examined regions of the body that could be vulnerable to Trim28 loss-of-function-induced toxicity. We assessed general morphology of the heart, liver and spleen and found no discernable defects in the adult knockout mice compared to littermate controls (Figure 4—figure supplement 2). Moreover, blood chemistry in these mice appeared normal (Figure 4—figure supplement 3).

Taken together, our study suggests that adult depletion of more than 75% of total Trim28 from the mouse body does not result in overt neurobehavioral phenotypes nor does it cause gross histological or biochemical defects. This is consistent with reports that deletion of TRIM28 in terminally differentiated muscle does not cause obesity (Dalgaard et al., 2016). These findings hold important implications for therapeutic targeting of Trim28 in diseases such as AD and PD where an inhibitor targeting TRIM28 may hold promise in the future with minimal side effects. Given the high expression of Trim28 in the adult mouse brain, additional characterization of these adult knockout animals will provide important insights into the potential of Trim28 downregulation in the context of disease; any physiological tradeoffs that may be incurred will thus be elucidated.

An important point of consideration moving forward into therapeutics is the mechanism by which TRIM28 regulates the steady state levels of α-Syn and tau. While our data suggest that TRIM28 forms a complex with α-Syn and tau (Rousseaux et al., 2016) and mediates their SUMOylation, we were not able to reconstitute this complex in a cell-free system, suggesting that other factors may be at play. Furthermore, while disruption of TRIM28 E3 ligase activity in vivo reduced α-Syn and tau levels, it likely did so by destabilization of TRIM28 itself. Thus, it is still unclear whether this inhibition represents a loss of enzymatic function or simply a structural loss. Further studies looking at the effect of this inhibition in adulthood or targeting other domains that may mediate TRIM28 SUMOylation may hold promise. For instance, the bromodomain of TRIM28 could be an alternative target given that a mutation in cysteine 651 to an alanine (C651A) reduces its SUMOylation activity on another target, VPS34 (Yang et al., 2013). Alternatively, SUMOylation of α-Syn and tau via Trim28 may only be a partial or bystander effect. Additional studies in cell-free systems and in organisms will thus be crucial to look for factors that mediate this relationship to yield global mechanistic insight on regulation. Most importantly, this study highlights the importance of testing the loss of function of lethal variants in the adult. While databases such as ExAC and GnomAD (Lek et al., 2016) offer a window into the pathogenicity of variants in development, it should not be the only factor guiding target selection; especially for neurodegenerative conditions where treatment will often only occur in the later decades of life.

No datasets were generated in this study. All data are presented in this manuscript.

1. 1. Antunes M
   2. Biala G

   (2012) The novel object recognition memory: neurobiology, test procedure, and its modifications

   Cognitive Processing 13:93–110.

   https://doi.org/10.1007/s10339-011-0430-z

   • PubMed
   • Google Scholar
2. 1. Barde I
   2. Rauwel B
   3. Marin-Florez RM
   4. Corsinotti A
   5. Laurenti E
   6. Verp S
   7. Offner S
   8. Marquis J
   9. Kapopoulou A
   10. Vanicek J
   11. Trono D

   (2013) A KRAB/KAP1-miRNA cascade regulates erythropoiesis through stage-specific control of mitophagy

   Science 340:350–353.

   https://doi.org/10.1126/science.1232398

   • PubMed
   • Google Scholar
3. 1. Cammas F
   2. Mark M
   3. Dollé P
   4. Dierich A
   5. Chambon P
   6. Losson R

   (2000)

   Mice lacking the transcriptional corepressor TIF1beta are defective in early postimplantation development

   Development 127:2955–2963.

   • PubMed
   • Google Scholar
4. 1. Cheng CT
   2. Kuo CY
   3. Ann DK

   (2014) KAPtain in charge of multiple missions: emerging roles of KAP1

   World Journal of Biological Chemistry 5:308–320.

   https://doi.org/10.4331/wjbc.v5.i3.308

   • PubMed
   • Google Scholar
5. 1. Czerwińska P
   2. Shah PK
   3. Tomczak K
   4. Klimczak M
   5. Mazurek S
   6. Sozańska B
   7. Biecek P
   8. Korski K
   9. Filas V
   10. Mackiewicz A
   11. Andersen JN
   12. Wiznerowicz M

   (2017) TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development

   Oncotarget 8:863–882.

   https://doi.org/10.18632/oncotarget.13273

   • PubMed
   • Google Scholar
6. 1. Dalgaard K
   2. Landgraf K
   3. Heyne S
   4. Lempradl A
   5. Longinotto J
   6. Gossens K
   7. Ruf M
   8. Orthofer M
   9. Strogantsev R
   10. Selvaraj M
   11. Lu TT
   12. Casas E
   13. Teperino R
   14. Surani MA
   15. Zvetkova I
   16. Rimmington D
   17. Tung YC
   18. Lam B
   19. Larder R
   20. Yeo GS
   21. O'Rahilly S
   22. Vavouri T
   23. Whitelaw E
   24. Penninger JM
   25. Jenuwein T
   26. Cheung CL
   27. Ferguson-Smith AC
   28. Coll AP
   29. Körner A
   30. Pospisilik JA

   (2016) Trim28 haploinsufficiency triggers Bi-stable epigenetic obesity

   Cell 164:353–364.

   https://doi.org/10.1016/j.cell.2015.12.025

   • PubMed
   • Google Scholar
7. 1. Fasching L
   2. Kapopoulou A
   3. Sachdeva R
   4. Petri R
   5. Jönsson ME
   6. Männe C
   7. Turelli P
   8. Jern P
   9. Cammas F
   10. Trono D
   11. Jakobsson J

   (2015) TRIM28 represses transcription of endogenous retroviruses in neural progenitor cells

   Cell Reports 10:20–28.

   https://doi.org/10.1016/j.celrep.2014.12.004

   • PubMed
   • Google Scholar
8. 1. Fellmann C
   2. Hoffmann T
   3. Sridhar V
   4. Hopfgartner B
   5. Muhar M
   6. Roth M
   7. Lai DY
   8. Barbosa IA
   9. Kwon JS
   10. Guan Y
   11. Sinha N
   12. Zuber J

   (2013) An optimized microRNA backbone for effective single-copy RNAi

   Cell Reports 5:1704–1713.

   https://doi.org/10.1016/j.celrep.2013.11.020

   • PubMed
   • Google Scholar
9. 1. Hay RT

   (2005) SUMO: a history of modification

   Molecular cell 18:1–12.

   https://doi.org/10.1016/j.molcel.2005.03.012

   • PubMed
   • Google Scholar
10. 1. Hirohama M
    2. Kumar A
    3. Fukuda I
    4. Matsuoka S
    5. Igarashi Y
    6. Saitoh H
    7. Takagi M
    8. Shin-ya K
    9. Honda K
    10. Kondoh Y
    11. Saito T
    12. Nakao Y
    13. Osada H
    14. Zhang KY
    15. Yoshida M
    16. Ito A

    (2013) Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2

    ACS Chemical Biology 8:2635–2642.

    https://doi.org/10.1021/cb400630z

    • PubMed
    • Google Scholar
11. 1. Ito-Ishida A
    2. Ure K
    3. Chen H
    4. Swann JW
    5. Zoghbi HY

    (2015) Loss of MeCP2 in Parvalbumin-and somatostatin-expressing neurons in mice leads to distinct rett syndrome-like phenotypes

    Neuron 88:651–658.

    https://doi.org/10.1016/j.neuron.2015.10.029

    • PubMed
    • Google Scholar
12. 1. Jakobsson J
    2. Cordero MI
    3. Bisaz R
    4. Groner AC
    5. Busskamp V
    6. Bensadoun JC
    7. Cammas F
    8. Losson R
    9. Mansuy IM
    10. Sandi C
    11. Trono D

    (2008) KAP1-mediated epigenetic repression in the forebrain modulates behavioral vulnerability to stress

    Neuron 60:818–831.

    https://doi.org/10.1016/j.neuron.2008.09.036

    • PubMed
    • Google Scholar
13. 1. Kim JY
    2. Ash RT
    3. Ceballos-Diaz C
    4. Levites Y
    5. Golde TE
    6. Smirnakis SM
    7. Jankowsky JL

    (2013) Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo

    European Journal of Neuroscience 37:1203–1220.

    https://doi.org/10.1111/ejn.12126

    • PubMed
    • Google Scholar
14. 1. Lasagna-Reeves CA
    2. Rousseaux MW
    3. Guerrero-Munoz MJ
    4. Vilanova-Velez L
    5. Park J
    6. See L
    7. Jafar-Nejad P
    8. Richman R
    9. Orr HT
    10. Kayed R
    11. Zoghbi HY

    (2015) Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows spinocerebellar ataxia type 1 phenotypes

    eLife 4:e10891.

    https://doi.org/10.7554/eLife.10891

    • PubMed
    • Google Scholar
15. 1. Lek M
    2. Karczewski KJ
    3. Minikel EV
    4. Samocha KE
    5. Banks E
    6. Fennell T
    7. O'Donnell-Luria AH
    8. Ware JS
    9. Hill AJ
    10. Cummings BB
    11. Tukiainen T
    12. Birnbaum DP
    13. Kosmicki JA
    14. Duncan LE
    15. Estrada K
    16. Zhao F
    17. Zou J
    18. Pierce-Hoffman E
    19. Berghout J
    20. Cooper DN
    21. Deflaux N
    22. DePristo M
    23. Do R
    24. Flannick J
    25. Fromer M
    26. Gauthier L
    27. Goldstein J
    28. Gupta N
    29. Howrigan D
    30. Kiezun A
    31. Kurki MI
    32. Moonshine AL
    33. Natarajan P
    34. Orozco L
    35. Peloso GM
    36. Poplin R
    37. Rivas MA
    38. Ruano-Rubio V
    39. Rose SA
    40. Ruderfer DM
    41. Shakir K
    42. Stenson PD
    43. Stevens C
    44. Thomas BP
    45. Tiao G
    46. Tusie-Luna MT
    47. Weisburd B
    48. Won HH
    49. Yu D
    50. Altshuler DM
    51. Ardissino D
    52. Boehnke M
    53. Danesh J
    54. Donnelly S
    55. Elosua R
    56. Florez JC
    57. Gabriel SB
    58. Getz G
    59. Glatt SJ
    60. Hultman CM
    61. Kathiresan S
    62. Laakso M
    63. McCarroll S
    64. McCarthy MI
    65. McGovern D
    66. McPherson R
    67. Neale BM
    68. Palotie A
    69. Purcell SM
    70. Saleheen D
    71. Scharf JM
    72. Sklar P
    73. Sullivan PF
    74. Tuomilehto J
    75. Tsuang MT
    76. Watkins HC
    77. Wilson JG
    78. Daly MJ
    79. MacArthur DG
    80. Exome Aggregation Consortium

    (2016) Analysis of protein-coding genetic variation in 60,706 humans

    Nature 536:285–291.

    https://doi.org/10.1038/nature19057

    • PubMed
    • Google Scholar
16. 1. Liang Q
    2. Deng H
    3. Li X
    4. Wu X
    5. Tang Q
    6. Chang TH
    7. Peng H
    8. Rauscher FJ
    9. Ozato K
    10. Zhu F

    (2011) Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7

    The Journal of Immunology 187:4754–4763.

    https://doi.org/10.4049/jimmunol.1101704

    • PubMed
    • Google Scholar
17. 1. Lu HC
    2. Tan Q
    3. Rousseaux MW
    4. Wang W
    5. Kim JY
    6. Richman R
    7. Wan YW
    8. Yeh SY
    9. Patel JM
    10. Liu X
    11. Lin T
    12. Lee Y
    13. Fryer JD
    14. Han J
    15. Chahrour M
    16. Finnell RH
    17. Lei Y
    18. Zurita-Jimenez ME
    19. Ahimaz P
    20. Anyane-Yeboa K
    21. Van Maldergem L
    22. Lehalle D
    23. Jean-Marcais N
    24. Mosca-Boidron AL
    25. Thevenon J
    26. Cousin MA
    27. Bro DE
    28. Lanpher BC
    29. Klee EW
    30. Alexander N
    31. Bainbridge MN
    32. Orr HT
    33. Sillitoe RV
    34. Ljungberg MC
    35. Liu Z
    36. Schaaf CP
    37. Zoghbi HY

    (2017) Disruption of the ATXN1-CIC complex causes a spectrum of neurobehavioral phenotypes in mice and humans

    Nature Genetics 49:527–536.

    https://doi.org/10.1038/ng.3808

    • PubMed
    • Google Scholar
18. 1. Neo SH
    2. Itahana Y
    3. Alagu J
    4. Kitagawa M
    5. Guo AK
    6. Lee SH
    7. Tang K
    8. Itahana K

    (2015) TRIM28 is an E3 ligase for ARF-Mediated NPM1/B23 SUMOylation that represses centrosome amplification

    Molecular and Cellular Biology 35:2851–2863.

    https://doi.org/10.1128/MCB.01064-14

    • PubMed
    • Google Scholar
19. 1. Oleksiewicz U
    2. Gładych M
    3. Raman AT
    4. Heyn H
    5. Mereu E
    6. Chlebanowska P
    7. Andrzejewska A
    8. Sozańska B
    9. Samant N
    10. Fąk K
    11. Auguścik P
    12. Kosiński M
    13. Wróblewska JP
    14. Tomczak K
    15. Kulcenty K
    16. Płoski R
    17. Biecek P
    18. Esteller M
    19. Shah PK
    20. Rai K
    21. Wiznerowicz M

    (2017) TRIM28 and interacting KRAB-ZNFs control self-renewal of human pluripotent stem cells through epigenetic repression of pro-differentiation genes

    Stem Cell Reports 9:2065–2080.

    https://doi.org/10.1016/j.stemcr.2017.10.031

    • PubMed
    • Google Scholar
20. 1. Pelossof R
    2. Fairchild L
    3. Huang CH
    4. Widmer C
    5. Sreedharan VT
    6. Sinha N
    7. Lai DY
    8. Guan Y
    9. Premsrirut PK
    10. Tschaharganeh DF
    11. Hoffmann T
    12. Thapar V
    13. Xiang Q
    14. Garippa RJ
    15. Rätsch G
    16. Zuber J
    17. Lowe SW
    18. Leslie CS
    19. Fellmann C

    (2017) Prediction of potent shRNAs with a sequential classification algorithm

    Nature Biotechnology 35:350–353.

    https://doi.org/10.1038/nbt.3807

    • PubMed
    • Google Scholar
21. 1. Rousseaux MW
    2. de Haro M
    3. Lasagna-Reeves CA
    4. De Maio A
    5. Park J
    6. Jafar-Nejad P
    7. Al-Ramahi I
    8. Sharma A
    9. See L
    10. Lu N
    11. Vilanova-Velez L
    12. Klisch TJ
    13. Westbrook TF
    14. Troncoso JC
    15. Botas J
    16. Zoghbi HY

    (2016) TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau

    eLife 5:e19809.

    https://doi.org/10.7554/eLife.19809

    • PubMed
    • Google Scholar
22. 1. Rousseaux MW
    2. Marcogliese PC
    3. Qu D
    4. Hewitt SJ
    5. Seang S
    6. Kim RH
    7. Slack RS
    8. Schlossmacher MG
    9. Lagace DC
    10. Mak TW
    11. Park DS

    (2012) Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease

    PNAS 109:15918–15923.

    https://doi.org/10.1073/pnas.1205102109

    • PubMed
    • Google Scholar
23. 1. Ruzankina Y
    2. Pinzon-Guzman C
    3. Asare A
    4. Ong T
    5. Pontano L
    6. Cotsarelis G
    7. Zediak VP
    8. Velez M
    9. Bhandoola A
    10. Brown EJ

    (2007) Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss

    Cell Stem Cell 1:113–126.

    https://doi.org/10.1016/j.stem.2007.03.002

    • PubMed
    • Google Scholar
24. 1. Singh K
    2. Cassano M
    3. Planet E
    4. Sebastian S
    5. Jang SM
    6. Sohi G
    7. Faralli H
    8. Choi J
    9. Youn HD
    10. Dilworth FJ
    11. Trono D

    (2015) A KAP1 phosphorylation switch controls MyoD function during skeletal muscle differentiation

    Genes & Development 29:513–525.

    https://doi.org/10.1101/gad.254532.114

    • PubMed
    • Google Scholar
25. 1. Sztainberg Y
    2. Chen HM
    3. Swann JW
    4. Hao S
    5. Tang B
    6. Wu Z
    7. Tang J
    8. Wan YW
    9. Liu Z
    10. Rigo F
    11. Zoghbi HY

    (2015) Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides

    Nature 528:123–126.

    https://doi.org/10.1038/nature16159

    • PubMed
    • Google Scholar
26. 1. Trono D

    (2015) Transposable elements, polydactyl proteins, and the genesis of human-specific transcription networks

    Cold Spring Harbor Symposia on Quantitative Biology 80:281–288.

    https://doi.org/10.1101/sqb.2015.80.027573

    • PubMed
    • Google Scholar
27. 1. Ure K
    2. Lu H
    3. Wang W
    4. Ito-Ishida A
    5. Wu Z
    6. He LJ
    7. Sztainberg Y
    8. Chen W
    9. Tang J
    10. Zoghbi HY

    (2016) Restoration of Mecp2 expression in GABAergic neurons is sufficient to rescue multiple disease features in a mouse model of rett syndrome

    eLife 5:e14198.

    https://doi.org/10.7554/eLife.14198

    • PubMed
    • Google Scholar
28. 1. Wang H
    2. Yang H
    3. Shivalila CS
    4. Dawlaty MM
    5. Cheng AW
    6. Zhang F
    7. Jaenisch R

    (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering

    Cell 153:910–918.

    https://doi.org/10.1016/j.cell.2013.04.025

    • PubMed
    • Google Scholar
29. 1. Wolf D
    2. Goff SP

    (2009) Embryonic stem cells use ZFP809 to silence retroviral DNAs

    Nature 458:1201–1204.

    https://doi.org/10.1038/nature07844

    • PubMed
    • Google Scholar
30. 1. Yang Y
    2. Fiskus W
    3. Yong B
    4. Atadja P
    5. Takahashi Y
    6. Pandita TK
    7. Wang HG
    8. Bhalla KN

    (2013) Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy

    PNAS 110:6841–6846.

    https://doi.org/10.1073/pnas.1217692110

    • PubMed
    • Google Scholar

Author details

1. Maxime WC Rousseaux

   1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States
   2. Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, United States

   Present address

   Department of Cellular and Molecular Medicine, University of Ottawa Brain and Mind Research Institute, University of Ottawa, Ontario, Canada

   Contribution

   Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-2737-6193

2. Jean-Pierre Revelli

   1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States
   2. Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, United States

   Contribution

   Data curation, Formal analysis, Validation, Methodology, Writing—review and editing

   Competing interests

   No competing interests declared

3. Gabriel E Vázquez-Vélez

   1. Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, United States
   2. Program in Developmental Biology, Baylor College of Medicine, Houston, United States
   3. Medical Scientist Training Program, Baylor College of Medicine, Houston, United States

   Contribution

   Formal analysis, Validation, Investigation, Methodology, Writing—review and editing

   Competing interests

   No competing interests declared

4. Ji-Yoen Kim

   1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States
   2. Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, United States

   Contribution

   Data curation, Validation, Investigation, Methodology

   Competing interests

   No competing interests declared

5. Evelyn Craigen

   1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States
   2. Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, United States

   Contribution

   Data curation, Investigation, Methodology

   Competing interests

   No competing interests declared

6. Kristyn Gonzales

   1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States
   2. Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, United States

   Contribution

   Data curation, Investigation, Methodology

   Competing interests

   No competing interests declared

7. Jaclyn Beckinghausen

   1. Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, United States
   2. Department of Neuroscience, Baylor College of Medicine, Houston, United States

   Contribution

   Data curation, Investigation, Methodology

   Competing interests

   No competing interests declared

8. Huda Y Zoghbi

   1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States
   2. Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, United States
   3. Program in Developmental Biology, Baylor College of Medicine, Houston, United States
   4. Department of Neuroscience, Baylor College of Medicine, Houston, United States
   5. Howard Hughes Medical Institute, Baylor College of Medicine, Houston, United States

   Contribution

   Conceptualization, Resources, Supervision, Funding acquisition, Writing—original draft, Project administration

   For correspondence

   hzoghbi@bcm.edu

   Competing interests

   Senior editor, eLife

   "This ORCID iD identifies the author of this article:" 0000-0002-0700-3349

• 3,250

  views

• 518

  downloads

• 49

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.